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Biochemical Correlates of Morphine Withdrawal. 2. Effects of
Clonidine1
Naloxone-precipitated morphine withdrawal in the rat has been
shown to deplete adrenal epinephrine and to increase adrenal
and locus ceruleus tyrosine hydroxylase activities. Administration
of clonidine (0.1-1 .0 mg/kg) through the first 6 hr of withdrawal
blocked adrenal epinepMne depletion in a dose-dependent fash-
ion. Clonidine also blocked the increases in tyrosine hydroxylase
activity seen in the adrenal and locus ceruleus during withdrawal.
Clonidine attenuated the weight loss and inhibited the diarrhea
dunng withdrawal. The a!pha-2 adrenergic antagonist yohimbine
reversed the effects of clonidine in blocking withdrawal. Morphine
withdrawal caused only a alight depletion of epnepMne in the
denervated adrenal; however, clonidine (0.3 mg/kg) prevented
this decrease. These results suggest that clonidine suppresses
adrenal and central adrenergic funcfion durrng morphine with-
drawal. This effect occurs through an alpha-2 adrenergic mach-
anism, possibly at the level of the locus ceruleus although
clonidine appears to also have a direct effect on the adrenal
medulla. The results are discussed in terms of adrenergic mech-
anisms of opiate withdrawal and the acfions of dorudine on this
syndrome.
The antihypertensive drug, clonidine, has been shown to be
effective in ameliorating many of the symptoms of opiate
withdrawal in humans (Gold et at, 1978a,b). The mechanism
by which clonidine blocks opiate withdrawal may involve the
suppression of locus ceruleus neurons. Clonidine is a potent
inhibitor of the firing rate of locus ceruleus neurons, and these
neurons are highly active during morphine withdrawal (Svens-
son et aL, 1975; Aghajanian, 1978). Biochemical studies have
shown that clonidine blocks the increase seen in rat brain
norepinephrine turnover during opiate withdrawal (Crawley et
at., 1979; Laverty and Roth, 1980). Whether clonidine causes a
decrease in synthesis or a decrease in release of catecholamine,
or both, remains to be elucidated.
Preliminary studies from this laboratory have shown that
increases in locus ceruleus and adrenal TH activities occur
during naloxone-precipitated morphine withdrawl (DiStefano
and Brown, 1982, 1983). This is consistent with the proposed
increase in turnover of catecholamines in adrenergic structures
during opiate withdrawal. In the preceding report we showed
that epinephrine appeared to be released selectively from the
adrenal medulla early in morphine withdrawal (DiStefano and
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Brown, 1985). In the present study clonidine was shown to
block this depletion of epinephrine from the adrenal; elevated
TH activity due to withdrawal was also suppressed by clonidine.
This suggests that clonidine reduces the turnover of catechol-
amines by decreassing both the synthesis and release of these
amines. It was also determined that clonidine acted mainly
through a central apha-2 adrenergic mechanism but that a
small, direct effect was evident in the adrenal medulla.
Materials and Methods
Clonidine dose-response. Male Sprague-Dawley rats (220-240 g)
were made physically dependent to morphine and subjected to nalox-
one-precipitated withdrawal as described in the preceding report
(DiStefano and Brown, 1985). Clonidine was given in doses of 0.1, 0.3
and 1.0 mg/kg (s.c.) 20 mm before the precipitation of withdrawal with
naloxone. These doses were repeated at 2 and 4 hr after naloxone
administration. Clonidine was given at these intervals because of its
short half-life in the rat (Jarrott and Spector, 1978). In this study it
was desired to maintain clonidine levels before initiating withdrawal
and during the withdrawal period. This drug treatment was also carried
out in rats treated with placebo pellets and naloxone to control for the
effects of clonidine. Also included was group of rats treated with
morphine and clonidine (no withdrawal syndrome precipitated). Rats
were sacrificed 6 hr after naloxone administration and the adrenal
glands and locus ceruleus were removed and assayed as described
previously (DiStefano and Brown, 1985) for the following adrenal
norepinephrine and epinephrine levels, adrenal TH activity and locus
ceruleus TH activity.
Coadministration of yohimbine and clonidine to rats un-
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dergoing withdrawal. In some rats yohimbine.HC1 (5 mg/kg s.c.)
was administered simultaneously with clonidine (0.3 mg/kg s.c) 20 mm
before precipitation of morphine withdrawal with naloxone. Yohimbine
and clonidine were administered again at 2 and 4 hr after withdrawal
and rats were sacrificed at 6 hr. This drug treatment was also carried
out in rats given placebo pellets to control for yohimbine and clonidine
drug effects.
Adrenal denervation studies. Unilaterally splanchnicotomized
rats (Taconic Farms, Inc., Germantown, NY) were treated with mor-
phine and withdrawal was precipitated as described (DiStefano and
Brown, 1985). In one group 0.3 mg/kg clonidine was given 20 rain
before naloxone and again at 2 and 4 hr after the onset of withdrawal.
Rats were sacrificed and both adrenals were removed and stored at
-70’C until assayed.
Drugs and chemicals. In addition to the agents described in the
preceding report (DiStefano and Brown, 1985), clonidine-HC1 was
kindly supplied by Boehringer-Ingelheim, Ltd., Inc. (Ridgefield, CT)
and yohimbine-HC1 was purchased from the Sigma Chemical Co. (St.
Louis, MO).
Statistics. Data were analyzed as described previously (DiStefano
and Brown, 1985).
Results
Clonidine dose-response studies. Figure 1 shows that
clonidine blocked the adrenal epinephrine depletion caused by
morphine withdrawal in a dose-dependent fashion. Clonidine
exerted this protective effect if given anytime up to 1 hr after
onset of withdrawal (data not shown). All doses tested gave
significant protection against adrenal epinephrine depletion
when compared to morphine withdrawal alone. Slight increases
in adrenal norepinephrine content were detected during with-
drawal and appeared to be blocked by clonidine. No changes in
catecholamine levels were observed in placebo-treated rats
given naloxone and clonidine or in rats administered morphine
and clonidine together. This indicates that clonidine had no
effect on adrenal catecholamine levels in naive or chronically
morphine-treated rats.
TH activities in the adrenal and locus ceruleus were also
measured (figs. 2 and 3). In a previous report (DiStefano and
Brown, 1985), we showed that morphine treatment alone sig-
nificantly elevated adrenal TH activity. Treatment of mor-
phine-dependent rats with three doses of0.3 mg/kg of clonidine
did not alter adrenal TH activity. However, clonidine blocked
the increase in TH activity due to morphine withdrawal in a
dose-dependent fashion. Doses of0.3 and 1.0 mg/kg of clonidine
lowered adrenal TH activity slightly below that seen with the
morphine plus clonidine treatment. In the locus ceruleus 0.1
mg/kg of clomdine was ineffective in lowering the TH activity
observed during morphine withdrawal (fig. 3); however, doses
of 0.3 and 1.0 mg/kg significantly blocked the increase in
enzyme activity in this tissue.
Clonidine also blocked the diarrhea and attenuated the
weight loss associated with morphine withdrawal (table 1).
Diarrhea occurred in all rats undergoing morphine withdrawal.
Administration of 0.1 mg/kg of clonidine blocked withdrawal
in half the rats tested (three of six), whereas doses of 0.3 mgI
kg of clonidine and above blocked diarrhea in all rats undergo-
ing morphine withdrawal. At 2 hr of withdrawal the weight loss
was attenuated approximately 25% with all doses of clonidine
used. However, at 4 and 6 hr the weight loss of the clonidine-
treated rats was the same as in the untreated rats undergoing
withdrawal.
Pharmacological characterization ofthe effect of don-
idine on morphine withdrawal. The alpha-2 adrenergic
antagonist yohimbine was coadministered with clonidine to
ascertain whether clonidine was acting through an alpha-2
adrenergic mechanism in blocking morphine withdrawal. Mor-
phine withdrawal caused a 55% depletion of adrenal epineph-
rime content and treatment with clonidine significantly atten-
uated this depletion (fig. 4). The concomitant administration
of yohimbine reversed the clonidine effect; depletion of epi-
nephrine to near morphine withdrawal levels was seen. Yohim-
bine alone (animals treated with placebo, clonidine and nalox-
one) decreased adrenal epinephrine content by 25% (fig. 4).
Therefore, of the total epinephrine depletion observed in the
morphine withdrawal group receiving clomdine and yohimbine
(40 nmol of epinephrine per adrenal) 15 nmol was due to an
Fig. 1. Dose-response of donkne
(CLON) in blocking adrenal epinephrine
(EPI) deplebon du#{241}ngaloxone (NAL)-
precipitated morphine (MORPH) with-
drawal. Rats were treated with CLON(0.3
mg/kg s.c.) 20 mm before NAL and at 2
and 4 tw after NAL adminIStratiOn. The
be (PLAC)-peleted rats also re-
calved the three kjections of CLON. Al
rats were killed at 6 hr. Values we mean
±S.E.M.,n=5to7.NE,noreplnephrlne;
CA, catecholamine  P < .01 compared
with control (CONT); t P < .01 compared







Fig. 2. Dose-response of donidine (CLON)
in blocking the adrenal Th activity increase
du#{241}ngmorphine (MORPH) withdrawal.
Rats were treated as in figure 1 . Values are
mean±S.E.M.,n=6to14.DA,dopamine;
PLAC, placebo; NAL, naloxone (  < .01
compared with MORPH plus CLON or con-
trol (CONT); t P < .01 compared with 0
mg/kg of CLON).
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Fig. 3. Dose-response of clonidine (CLON) ui
blocking the locus ceruleus (LC) TH activity ale-
vation due to morphine withdrawal. Anki&s were
treated as in figure 1. Values are mean ± S.E.M.,
n = 7 to 20. DA, dopamine; PLAC, placebo; NAL,
naloxone ( P < .05 compared with control
(CONT); t P < .05 compared with 0 mg/kg of
CLON).
undetermined effect of yohimbine and 25 nmol was due to its
apha-2 antagonist effect. In fact, 25 nmol of epinephrine per
adrenal was the exact difference in adrenal epinephrine content
between rats undergoing morphine withdrawal and those rats
in which morphine withdrawal was treated with clonidine. This
indicates that the effect of clonidine on morphine withdrawal
is blocked completely by yohimbine.
Coadministration of yohimbine with clonidine had a dra-
matic effect on the withdrawal-induced diarrhea response (table
1). Whereas none of the withdrawal rats treated with clonidine
had diarrhea, all of the withdrawal rats treated with yohimbine
plus clonidine exhibited diarrhea. However, the weight loss in
the yohimbine-treated animals remained attenuated as in the
morphine withdrawal rats treated with clonidine.
Adrenal denervation studies. In our preceding report
(DiStefano and Brown, 1985), we showed that the adrenal
epinephrine depletion observed during naloxone-precipitated
morphine withdrawal was mediated mainly through a central
mechanism via the splanchnic nerves; a small direct mechanism
was also present. These experiments have been repeated here
to determine whether clonidine can block this direct effect of
withdrawal on adrenal catecholamine levels. Figure 5 shows
that the epinephrine content was decreased during withdrawal
in both the innervated and denervated adrenals, but that the
effect was more pronounced in the innervated gland. When
clonidine was administered to these animals the epinephrine
content was restored to control values in both the innervated
and denervated adrenals.
Discussion
Suppression of morphine withdrawal by clonidine.
The results presented here show that the apha-2 adrenergic
agonist, clonidine, effectively blocked naloxone-precipitated
morphine withdrawal in a dose-dependent fashion. The clinical
efficacy of clonidine in treating opiate withdrawal has been
documented by Gold et at. (1978a,b, 1980). Monitoring a battery
of withdrawal signs, they reported the amelioration of opiate
withdrawal with very low doses of clonidine. In the rat, cloni-
CONT MORPH MORPH MORPH PLAC
SAL CLON clON YOH CLON YOH
NAL NAL NM- NAL
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TABLE 1
Morphine withdrawal-induced weight loss and diarrhea In rats
treated with clonidine and yohimbine
Weight loss, k grams, is given as mean ± S.E.M. of 6 to 14 rats. Incidence of
diarrhea is expressed as number of animals exhibng diarrhea/number of animals
in treatmentgroup. MORPH, morphine; /D, withdrawal; CLON, clonidine; YOHIM,
-.
Treatment wt. kIss kldden o(
21w 6hr
g
COntrol 3±1 6±1 0/14
MORPH W/D 23 ± 2 26 ± 2 13/14
+CLON, 0.1 mg/kg 17 ± 2 22 ± 2 3/6
+CLON, 0.3 mg/kg 18 ± 2 24 ± 2 0/7
i-CLON, 1 .0 mg/kg 17 ± 1 25 ± 2 0/7
+CLON, 0.3 mg/kg
+YOHIM, 5 mg/kg 14 ± 1 22 ± 1 7/7
‘C
I
Fig. 4. Pharmacolo characterizaon of clonidine (CLON) in blocking
adrenal epinephrine (EPI) depletion during naloxone (NAL)-precipitated
morphine (MORPH) wfthdrawal. Rats received 0.3 mg/kg of CLON 20
mm before and at 2 and 4 hr after NAL. One group received 5 mg/kg of
yohimbine (YOH) with each CLON injectlon. One group received placebo
(PLAC) pellets to control for drug injections. Rats were killed 6 hr after
NAL. Values are mean ± S.E.M., n = 7 in each group. SAL, saline; NE,
norepinephrine; CA, catecholamine (e P < .01 compared with CONT;
t P < .01 compared with MORPH plus CLON plus NAL).
dine blocks the number of wet dog shakes (Tseng et at., 1975),
weight loss (Meyer and Sparber,1976), diarrhea (Nakaki et at.,
1981) and elevated blood pressure (Buccafusco, 1983) associ-
ated with naloxone-precipitated morphine withdrawal. Our re-
suits showing attenuated weight loss and diarrhea with cloni-
dine treatment of withdrawal in rats support the findings of
Meyer and Sparber (1976) and Nakaki et at. (1981) and support
this as a useful animal model for studying the mechanism of
action of clonidine in blocking opiate withdrawal.
Hyperactivity of central noradrenergic neurons, especially in
the locus ceruleus, has been implicated in the initiation and
maintenance of the opiate withdrawal syndrome (Gold et at.,
1978b, 1980). It has been shown that opiates (Korfet at., 1974),
enkephalins (Young et al., 1977) and clonidine (Svensson et at.,
1975) all decrease the firing rate of locus ceruleus neurons.
Aghajanian (1978) demonstrated that withdrawal from chronic
opiate treatment in rats resulted in an abrupt disinhibition and
subsequent hyperactivity of locus ceruleus neurons. lontopho-
resis of clonidine or morphine to these neurons decreased their
firing rate. He suggested that clonidine blocks withdrawal by
inhibiting the firing of these neurons through an a4,ha-2 ad-
renergic receptor mechanism, as the apha-2 selective antago-
nist, piperoxane, reversed the effect of clonidine but not that
of morphine. Therefore, it appears that opiates and clonidine
have parallel but independent effects on locus ceruleus neurons.
The biochemical studies reported here support the hypothesis
that increased adrenergic activity plays an important role in
morphine withdrawal and that clonidine blocks withdrawal by
suppressing this adrenergic activity. We have shown that TH
activity in the locus ceruleus was elevated during morphine
withdrawal and that clonidine was capable of blocking this
increase in a dose-dependent fashion (fig. 3). We also demon-
strated that the adrenal TH activity increase and epinephrrne
depletion caused by morphine withdrawal are blocked by don-
idine (figs. 1 and 2). These results suggest that during with-
drawal the turnover (synthesis and release) of catecholamines
increases by a mechanism that is prevented by clonidine. In-
deed, increases in brain norepinephrine turnover seen during
morphine withdrawal in the rat were prevented by clonidine
(Laverty and Roth, 1980) or guanfacine (Zigun et at., 1981).
These changes in norepinephrine turnover parallel the changes
in locus ceruleus TH activity demonstrated in this study during
morphine treatment, morphine withdrawal and clonidine-
treated morphine withdrawal.
Other loci rich in both apha-2 adrenergic and opiate recep-
tore have been implicated as sites in which clonidine might act
to suppress the opiate withdrawal syndrome (Young and Kiu-
har, 1980; Franz et at., 1982; Unnerstall et at., 1981). A recent
study concluded that forebrain projections of the locus ceruleus
do not mediate opiate withdrawal behavior (Britton et at., 1984).
Clonidine was found as effective at suppressing withdrawal
signs in sham-operated rats as in those with 6-hydroxydopa-
mine lesions of the dorsal noradrenergic bundle. However, this
study failed to demonstrate norepinephrine losses in the locus
ceruleus and related areas of the lesioned animals.
Pharmacological characterization of clonidine in
blocking withdrawal. The results shown in figure 4 and
table 1 provide strong evidence that clonidine acts through
apha-2 adrenoceptors to decrease nonadrenergic activity and
thus block opiate withdrawal. The aipha- antagonist, yohim-
bine, completely reversed the effects ofclonidine on the adrenal
epinephrine depletion (fig. 4) and the diarrhea (table 1) result-
ing from morphine withdrawal. Nakaki et at. (1981) also showed
that cionidine inhibited the diarrhea caused by morphine with-
drawal in rats; this effect was reversed by coadministration of
yohimbine. The blockade of withdrawal-induced diarrhea by
clonidine may occur through apha-2 adrenoceptors located on
intestinal smooth muscle and not in the brain (Hughs et at.,
1978; Gillan et at., 1979).
Meehanism by which clonidine affeets adrenal func-
tion during morphine withdrawal. Clonidine may inhibit
epinephrme depletion (apparent release) and TH activity dur-
ing morphine withdrawal through one or a combination of three
mechanisms: 1) clonidine may decrease splanchnic nerve activ-
ity to the adrenal by acting at central apha-2 adrenergic
receptors; 2) clonidine may decrease preganglionic cholinergic




Fig. 5. Effect of unilateral splanchnicotomy on
adrenal epinephrlne (EPI) content in control
(CONT), morphkie withdrawal (MORPH W/D)
and MORPH W/D plus dondine (CLON)-
treated rats. Rats were prepared as described
In the text. Values are mean ± S.E.M., n = 6
to 16 (**p < .01; P < .05 compared with
CONT or MORPH W/D plus CLON).
CONT MORPH MORPH CONT MORPH MORPH
W,D WID W/D W/D
CLONCLON












exert a direct effect on adrenal chromaffin cells to inhibit the
release of catecholamines.
The results shown in figure 5 strongly suggest that the greater
part of the action of clonidine in blocking withdrawal occurs
through the splanchnic nerve. Although clonidine prevents
withdrawal-induced epinephrine depletion in both the inner-
vated and denervated adrenal, it is apparent that the neurally
mediated component is predominant. Because adrenal cate-
cholamine release (Marley and Prout, 1965) and TH activity
(Weiner et at., 1972) are proportional to the rate of splanchnic
nerve discharge, it is probable that clonidine is acting mainly
through a central mechanism to prevent adrenal epinephrine
depletion during opiate withdrawal.
Clonidine may also affect the spianchnic nerve ending to
inhibit the release of acetylchoiine. Schumann and Werner
(1971) showed that compound BAY a6781, which is structurally
and pharmacologically similar to clonidine, blocked cholinergic-
stimulated catecholamine release in the isolated, perfused bo-
vine adrenal. No effect of BAY a6781 was seen on the unstim-
ulated preparation, implying that this drug inhibited the liber-
ation of acetylcholine from the splanchnic nerve.
Finally, clonidine may exert a direct effect on the adrenal
medulla. Our results from the denervated adrenal demonstrated
that the slight depletion of epinephrine seen in morphine
withdrawal was blocked by clonidine (fig. 5). Togashi (1983)
has shown recently that the i.v. administration of clonidine
decreased basal adrenal catecholamine release in rats by both
a central and a direct mechanism, with the former being pre-
dominant. Alpha-2 adrenoceptors have been characterized
pharmacologically on the cell bodies of sympathetic ganglia,
and activation of these receptors has been implicated in the
hyperpolarization of ganglia cells (Brown and Caulfield, 1979).
Also, Wada et at. (1982) have characterized high affinity, sat-
urable [3HJclonidine binding sites on bovine adrenal medullary
cells in suspension. It is possible that clonidine acts directly on
adrenal apha-2 adrenergic receptors to suppress the epineph-
rine depletion observed during withdrawal. However, this
mechanism probably constitutes only a small part of the total
action of clonidine in blocking opiate withdrawal.
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